RANDOMIZED, DOUBLE BLIND MULTICENTER PHASE II STUDY OF TIME TO PROGRESSION ON FULVESTRANT IN COMBINATION WITH ERLOTINIB OR PLACEBO IN HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER (MBC) SUBJECTS WHO PROGRESSED ON FIRST LINE HORMONAL THERAPY: